Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin Repeat-Dose Safety and Efficacy for Glabellar Frown Lines
NCT00512135Phase 3Completed
- Sponsor
- Merz
- Start
- Jun 2007
- Primary completion
- Dec 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of incobotulinumtoxinA in glabellar lines, sponsored by Merz. Primary endpoints: Incidence of Adverse Events (AEs), Incidence of Adverse Events of Special Interest (AESI) and 7 more. Started Jun 2007; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT00512135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00512135.